awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q48390325-60B9F763-F8A6-4004-84E2-8A62CB6E088B
Q48390325-60B9F763-F8A6-4004-84E2-8A62CB6E088B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48390325-60B9F763-F8A6-4004-84E2-8A62CB6E088B
Vortioxetine: first global approval.
P2860
Q48390325-60B9F763-F8A6-4004-84E2-8A62CB6E088B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48390325-60B9F763-F8A6-4004-84E2-8A62CB6E088B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d7efbcc5ad09ecec2fa4339128169eba7e5c7f0a
P2860
A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.